Division of Research
Preclinical and Diagnostic Molecular Imaging Laboratory
Amyloid diseases; preclinical imaging; development of amyloid-targeting agents
Ph.D. University of Tennessee, Department of Comparative and Experimental Medicine, Knoxville , TN (2010 - 2014)
B.Sc. University of Tennessee, Department of Biochemistry, Cellular and Molecular Biology, Knoxville, TN (2005 - 2009)
2014 International Symposium on Amyloidosis
Best Oral Presentation: "Detection of cardiac amyloidosis by SPECT/CT imaging using both 125I-serum amyloid P component and the novel 125I-p5R+14 peptide"
2013 World Molecular Imaging Congress
Best Poster Presentation: "Evaluation of SPECT detection of cardiac amyloidosis in mice by using 125I-p5R+14 peptide or 125I-SAP"
2012 International Symposium on Amyloidosis
Best Presentation: "The amyloidophilic peptide p5 binds rapidly and stably to visceral amyloid in vivo--A potential radiotracer for PET/CT imaging"
Wall JS, Heidel RE, Stuckey A, Martin EB, Richey T, Williams A, Foster JS, Whittle B, Fu Y, Powell D, Lands RH, Guthrie S, Kennel SJ.
Detection of systemic AL amyloidosis and differentiation of AL from Attr using 124I-p5+14 PET imaging. Blood. 2020 Nov;136(Sup 1):17–18. Available in Scopus: Dec 2020.
Martin EB, Wall JS.
Looking for amyloid in all the right places. Journal of Cardiac Failure. 2020 Oct 5:S1071-9164(20)31470-6.
Wall JS, Stuckey A, Martin EB, Richey T, Williams A, Wooliver DC, Macy S, Foster JS, Whittle B, Geldrich R, Powell M, Fu Y, Powell D, Osborne D, Heidel RE, Marine B, Besozzi M, Ramchandren R, Lands RH, Kennel SJ.
Preliminary phase 1 data on the safety and efficacy of a novel PET radiotracer, 124I-p5+14, for imaging systemic amyloidosis. Blood. 2019 Nov;134(Supplement_1):3034-3034.
Richey T, Foster JS, Williams AD, Williams AB, Stroh A, Macy S, Wooliver C, Heidel RE, Varanasi SK, Ergen EN, Trent DJ, Kania SA, Kennel SJ, Martin EB, Wall JS.
Macrophage-mediated phagocytosis and dissolution of amyloid-Like fibrils in mice, monitored by optical imaging. The American Journal of Pathology. 2019 May;189(5):989-998. Epub 2019 Feb 6.
Wall JS, Williams AD, Foster JS, Richey T, Stuckey A, Macy S, Wooliver C, Campagna SR, Tague ED, Farmer AT, Lands RH, Martin EB, Heidel RE, Kennel SJ.
Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America. 2018 Nov 13;115(46):E10839-E10848. Epub 2018 Oct 30.
Martin EB, Williams AD, Heidel RE, Foster JS, Lands RH, Kennel SJ, Wall JS.
A functional assay to identify amyloidogenic light chains. Amyloid. 2018 Mar 23:1-8.
Martin EB, Williams A, Richey T, Wooliver C, Stuckey A, Foster JS, Kennel SJ, Wall JS.
Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides. Journal of Translational Medicine. 2017 Dec 11;15(1):247. [Epub ahead of print]
Blancas-Mejia L, Martin EB , Williams A, Wall JS, Ramirez-Alvarado M.
Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients. Biophysical Chemistry. 2017 Nov;230:89-98. Epub 2017 Sep 1.
Wall JS, Williams A, Richey T, Stuckey A, Wooliver C, Scott JC, Donnell R, Martin EB, Kennel SJ.
Specific amyloid binding of polybasic peptides in vivo is retained by beta-sheet conformers but lost in the disrupted coil and all D-amino acid variants. Molecular Imaging and Biology. 2017 Oct;19(5):714-722.
Foster JS, Williams AD, Macy S, Richey T, Stuckey A, Wooliver DC, Koul-Tiwari R, Martin EB, Kennel SJ, Wall JS.
A peptide-Fc opsonin with pan-amyloid reactivity. Frontiers in Immunology. 2017 Sep 4;8:1082.
Wall JS, Foster JS, Martin EB, Kennel SJ.
Pretargeting immunotherapy: A novel treatment approach for systemic amyloidosis. Pharmaceutical Patent Analyst. 2017 Sep;6(5):215-223. Epub 2017 Aug 21.
Wall JS, Kennel SJ, Martin EB.
Dual-energy SPECT and the development of peptide p5+14 for imaging amyloidosis. Molecular Imaging. 2017 May;16:1536012117708705.
Martin EB, Williams A, Wooliver C, Heidel RE, Adams S, Dunlap J, Ramirez-Alvarado M, Blancas-Mejia LM, Lands RH, Kennel SJ, Wall JS.
Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. PLoS One. 2017 Mar 28;12(3):e0174152. eCollection 2017.
Wall JS, Williams A, Wooliver C, Martin EB, Cheng X, Heidel RE, Kennel SJ.
Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization. Biochemistry and Biophysics Reports. 2016 Dec;8:89-99. Epub 2016 Aug 11.
Reynolds BH, Martin E, Williams A, Akpa B, Ferris J, Heidel E, Baveja S, Dhand R. Do plasma levels of biomarkers reflect muscle injury in patients admitted to the floors in acute care hospitals? Presented at American Thoracic Society International Conference; 2018 May 18-23; San Diego, CA.
Wall JS, Foster JS, Koul R, Williams A, Martin EB, Richey T, Stuckey A, Macy S, Lands R, Hanna W, Kennel SJ. A novel bifunctional peptide-FC-fusion construct for immunotherapy of visceral amyloidosis. Presented at 58th American Society of Hematology Annual Meeting and Exposition; 2016 Dec 3-6; San Diego, CA.
Martin EB, Williams A, Heidel RE, Adams S, Lands R, Hanna W, Kennel SJ, Wall JS. A method to predict the amyloidogenic propensity of light chain proteins by measuring binding to synthetic amyloid fibrils. Presented at 58th American Society of Hematology Annual Meeting and Exposition; 2016 Dec 3-6; San Diego, CA.Top
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2019